Skip to main content

EarlyHealth Group Acquires Corena to Drive $100M Growth in Türkiye’s Life Sciences Sector

Written by Customer Service on . Posted in Mergers And Acquisitions.

ANKARA, Türkiye, June 17, 2025 (GLOBE NEWSWIRE) — EarlyHealth Group, a global pharmaceutical service provider, today announced the acquisition of Corena Ecza Deposu, Türkiye’s leading pharmaceutical distributor, strengthening its position as one of the largest service providers dedicated to the life sciences sector in Türkiye.

This acquisition supports EarlyHealth Group’s strategy to drive a $100 million portfolio of initiatives aimed at globalizing the Turkish pharmaceutical environment.

EarlyHealth Group x Corena Acquisition 1

“By combining Corena’s national expertise with our international platform, we are positioned to accelerate government-led export initiatives, strengthen academic-industry collaborations, and advance Türkiye’s role in clinical research and pharmaceutical innovation,” explained Dr. Dan A. Renout, Chief Executive Officer of EarlyHealth Group.

Mrs. Nihal Aygün, Owner of Corena, stated “Our collaboration with EarlyHealth Group spans nearly two decades. This acquisition and strategic partnership reinforce our joint commitment to national priorities, specifically supporting Türkiye’s efforts to reduce pharmaceutical import dependency and positioning the country as a key contributor to the global pharmaceutical supply chain.” As part of EarlyHealth Group, Corena will spearhead these strategic initiatives across Türkiye, serving as the operational and scientific hub to advance ongoing bilateral cooperation.

EarlyHealth Group x Corena Acquisition 2

The ceremonial signing took place in Dubai, United Arab Emirates, under the presence of His Excellency Onur Saylan, Consul General of the Republic of Türkiye. Distinguished guests included H.H. Sheikh Khalifa bin Khalid Al Hamed, member of the Abu Dhabi Royal Family, Her Excellency Dr. Annalee Babb, Ambassador of Barbados to the UAE, and Mr. Ahmed Emre Büyükkılıç, Country Advisor to the Investment Office of the Presidency of the Republic of Türkiye. Mr. Saylan concluded the event by stating “This partnership exemplifies the spirit of strategic cooperation between Türkiye and the United Arab Emirates. It underscores our shared commitment to advancing healthcare innovation, fostering cross-border investment, and building a platform for sustainable growth that benefits future generations.”

About EarlyHealth Group
EarlyHealth Group (EHG) is a global pharmaceutical service provider supporting clinical research and market access to the life sciences industry. Website: www.early-health.com

About Corena
Corena is a leading Turkish pharmaceutical company with over 20 years of trusted service supporting healthcare market access and distribution. Website: www.corena.com.tr

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b492447-f33d-4022-a555-67a19f805195

https://www.globenewswire.com/NewsRoom/AttachmentNg/e6470fea-622f-49d0-a8f5-724f4d4f82fd

CONTACT: For media inquiries, please contact:
EarlyHealth Group Communications
Email: press@early-health.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.